Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties.
Novel compounds have been developed that (in many cases) inhibit cholinesterases and concomitantly interact with at least one further pharmacological target, such as 5-HT3 or H3 receptors. But also enzymes like monoamine oxidase and the serotonin transporter have been targeted. Hybrid molecules can also incorporate antioxidant or neuronal Ca2+-channel-blocking structures.
Decker
Michael
M
Lehrstuhl für Pharmazeutische/Medizinische Chemie, Institut für Pharmazie, Philosophenweg 14, D-07743 Jena, Germany. m.decker@uni-jena.de
D000544:Alzheimer Disease / Q000517:prevention & control*; D000647:Amnesia / Q000517:prevention & control*; D000818:Animals; D002121:Calcium Channel Blockers / Q000737:chemistry / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D015394:Molecular Structure; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000737:chemistry / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D002800:Cholinesterase Inhibitors; D008996:Monoamine Oxidase Inhibitors; D012702:Serotonin Antagonists